Difference between revisions of "Team:ETH Zurich"

Line 60: Line 60:
  
 
     <figure>
 
     <figure>
−
    <img src="https://static.igem.org/mediawiki/2017/9/99/T--ETH_Zurich--CH.png" class="CH" style="float:right;width: 350px;height:auto;">
+
        <img src="https://static.igem.org/mediawiki/2017/9/99/T--ETH_Zurich--CH.png" class="CH" style="float:right;width: 350px;height:auto;">
 
     </figure>
 
     </figure>
 
      
 
      
Line 67: Line 67:
  
 
<section id="second" class="step invert">
 
<section id="second" class="step invert">
 +
    <figure>
 +
        <img src="https://static.igem.org/mediawiki/2017/0/02/T--ETH_Zurich--Ec.png" class="Ec"  style="float:left;width: 240px;height:auto;">
 +
    </figure>
 
     <div>
 
     <div>
 
       CATE consists of the non-pathogenic bacterium  E. coli Nissle that has the intrinsic ability to home specifically in tumors. We are engineering E. coli Nissle to carry a MRI  
 
       CATE consists of the non-pathogenic bacterium  E. coli Nissle that has the intrinsic ability to home specifically in tumors. We are engineering E. coli Nissle to carry a MRI  
Line 74: Line 77:
 
       <a href="https://2017.igem.org/Team:ETH_Zurich/Description" class="more">Project description</a>
 
       <a href="https://2017.igem.org/Team:ETH_Zurich/Description" class="more">Project description</a>
 
     </div>
 
     </div>
−
     <img src="https://static.igem.org/mediawiki/2017/0/02/T--ETH_Zurich--Ec.png" class="Ec"  style="float:left;width: 240px;height:auto;">
+
      
 
    
 
    
 
</section>
 
</section>

Revision as of 09:30, 19 October 2017

Cancer kills over 8 million people every year. That's the entire population of Switzerland!

We need more specific therapies because current approaches result in many side-effects. Thats why we invented CATE, the first all-in-one living cancer therapeutic with an integrated two-step safety mechanism.

That's why we created CATE: Cancer-Targeting E. coli.

Learn more
CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home specifically in tumors. We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.

Project description

CATE is administered intravenously, travels through the blood and colonizes tumors where the bacteria form a highly dense layer between the live and dead zone of the tumor

The high density of bacterial cells and the overproduction of lactate by the tumor together activate the first steps of CATE.

Design

CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home specifically in tumors.

We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.

Project description